227 related articles for article (PubMed ID: 22650254)
1. P53 mdm2 inhibitors.
Khoury K; Dömling A
Curr Pharm Des; 2012; 18(30):4668-78. PubMed ID: 22650254
[TBL] [Abstract][Full Text] [Related]
2. How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
Estrada-Ortiz N; Neochoritis CG; Dömling A
ChemMedChem; 2016 Apr; 11(8):757-72. PubMed ID: 26676832
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner.
Fry DC
Curr Pharm Des; 2012; 18(30):4679-84. PubMed ID: 22650256
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
5. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
6. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
7. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
8. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
10. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
[TBL] [Abstract][Full Text] [Related]
11. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
12. A re-examination of the MDM2/p53 interaction leads to revised design criteria for novel inhibitors.
Vasilevich NI; Afanasyev II; Kovalskiy DA; Genis DV; Kochubey VS
Chem Biol Drug Des; 2014 Nov; 84(5):585-92. PubMed ID: 24797588
[TBL] [Abstract][Full Text] [Related]
13. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.
Fry DC; Graves B; Vassilev LT
Methods Enzymol; 2005; 399():622-33. PubMed ID: 16338385
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
17. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
18. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
[No Abstract] [Full Text] [Related]
19. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
[TBL] [Abstract][Full Text] [Related]
20. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]